What's in a word? For Moderna, the answer is survival. The biotech company has shifted from vaccines to 'individualized neoantigen therapies' amid vaccine skepticism, aiming to avoid public backlash and regulatory hurdles.

The change is more than semantic. It reflects a complex interplay of politics and public perception. While some see it as a necessary tactical move, others argue it risks misleading patients about the nature of their treatments.

Moderna's strategy appears to be working for now; the US government has remained quiet on the matter, allowing the company to continue its research unimpeded. However, the naming game continues to play out in a broader context of public health and trust.

The logic behind the rebranding is clear: vaccines are associated with fear, while therapies evoke hope. But as the stakes get higher, so does the pressure on companies like Moderna to walk the tightrope between scientific innovation and public perception.

Ultimately, whether this wordplay will pave a path to curing cancer or merely sow confusion remains to be seen. What is certain is that in the battle for our health, language matters just as much as medicine itself.